Ann: Zantrene Improves Immune Therapy Treatment of Melanoma, page-39

Todays announcement is truly fabulous.These PC results illustrate Zantrenes potential to enhance AND compliment the anti-melanoma immune response.

PD-1 inhibitors created a paradigm shift in cancer immunotherapy.

When I think PD-1 inhibitors Keytruda (Merck) and Opdivo (Bristol Myers) spring to mind. If Zantrene synergises to overcome checkpoint inhibitor resistance and Keytruda success rate in patients is only ~ 15%. How many billions is Zantrene potentially worth to a company like Merck if their 15% success rate could be improved even by only 10-20% ?

Can't wait to watch how this all plays out the next 18 months !